Neal D. Shore, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Swetha Sridharan, Klaus Brasso, Henry H. Woo, Antonio Gómez Caamaño, Luke Nordquist, Yiyun Tang, Ruslan Croitoru, Matt Rosales, Matko Kalac, Olivier Peraud, Fong Wang, Stephen J. Freedland. "Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.e17127